Outcome of cephalosporin treatment of bacteremia due to CTX-M–type extended-spectrum β-lactamase–producing Escherichia coli

Brun-Buisson, 1987, Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae, Lancet, 2, 302, 10.1016/S0140-6736(87)90891-9

Emery, 1997, Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center, J. Clin. Microbiol., 35, 2061, 10.1128/JCM.35.8.2061-2067.1997

Fantin, 1990, Activity of sulbactam in combination with ceftriaxone in vitro and in experienced endocarditis caused by Escherichia coli producing SHV-2 like β-lactamase, Antimicrob. Agents Chemother., 34, 581, 10.1128/AAC.34.4.581

Garner, 1988, CDC definitions for nosocomial infections, Am. J. Infect. Control, 16, 128, 10.1016/0196-6553(88)90053-3

Herbert, 1993, A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome, Chest, 104, 230, 10.1378/chest.104.1.230

Ho, 2002, Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamases: a case-control study of risk factors and outcomes, Scand. J. Infect. Dis., 34, 567, 10.1080/00365540210147516

Jacoby, 2005, The new β-lactamases, N. Engl. J. Med., 352, 380, 10.1056/NEJMra041359

Jones, 2003, Experience with ESBL-producing Enterobacteriaceae (ENT) treated with carbapenem compared to other β-lactams: outcomes report from the Sentry antimicrobial surveillance program

Jones, 2005, Reevaluation of Enterobacteriaceae MIC/disk diffusion zone regression scattergrams for nine β-lactams: adjustments of breakpoints for strains producing extended-spectrum β-lactamases, Diagn. Microbiol. Infect. Dis., 52, 235, 10.1016/j.diagmicrobio.2005.02.006

Jones, 1998, Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States, Diagn. Microbiol. Infect. Dis., 30, 215, 10.1016/S0732-8893(97)00234-4

Kang, 2004, Bloodstream infections due to extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy, Antimicrob. Agents Chemother., 48, 4574, 10.1128/AAC.48.12.4574-4581.2004

Li, 2003, Dissemination and spread of CTX-M extended-spectrum beta-lactamases among clinical isolates of Klebsiella pneumoniae in central China, Int. J. Antimicrob. Agents, 22, 521, 10.1016/S0924-8579(03)00157-2

Medeiros, 1993, Nosocomial outbreaks of multiresistant bacteria: extended-spectrum β-lactamases have arrived in North America, Ann. Intern. Med., 119, 428, 10.7326/0003-4819-119-5-199309010-00015

National Committee for Clinical Laboratory Standards, 1999

Naumovaski, 1992, Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients, Antimicrob. Agents Chemother., 36, 1991, 10.1128/AAC.36.9.1991

Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended spectrum β-lactamases: implications for the clinical microbiology laboratory, J. Clin. Microb., 39, 2206, 10.1128/JCM.39.6.2206-2212.2001

Pitout, 2004, Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes, Clin. Infect. Dis., 38, 1736, 10.1086/421094

Pottumarthy, 2005, Susceptibility testing accuracy of a CTX-M–type extended-spectrum β-lactamase organism–producing population of Enterobacteriaceae: intermethod analysis for 9 β-lactams, Diagn. Microbiol. Infect. Dis., 53, 131, 10.1016/j.diagmicrobio.2005.02.012

Rahal, 1998, Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella, JAMA, 280, 1233, 10.1001/jama.280.14.1233

Rice, 1991, Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model, Antimicrob. Agents Chemother., 35, 1243, 10.1128/AAC.35.6.1243

Smith, 1990, Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamases, Antimicrob. Agents Chemother., 34, 1290, 10.1128/AAC.34.6.1290

Thauvin-Eliopoulos, 1997, Efficacies of piperacillin–tazobactam and cefepime in rats with experienced intra-abdominal abscesses due to an extended-spectrum β-lactamase–producing Klebsiella pneumoniae, Antimicrob. Agents Chemother., 41, 1053, 10.1128/AAC.41.5.1053

Wang, 2003, Clinical isolates of Enterobacteriaceae producing extended-spectrum lactamases prevalence of CTX-M-3 at a hospital in China, Antimicrob. Agents Chemother., 47, 790, 10.1128/AAC.47.2.790-793.2003

Wong-Beringer, 2002, Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime, Clin. Infect. Dis., 34, 135, 10.1086/324742